Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase I Trial of Vorinostat (MK0683, SAHA) in Combination With Decitabine in Patients With AML or MDS.
This study is ongoing, but not recruiting participants.
Study NCT00479232 Information provided by Merck
First Received: May 24, 2007 Last Updated: March 3, 2010
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Preleukemia
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Neoplasms by Histologic Type
Precancerous Conditions
Interventions listed in this trial
Comparator: vorinostat (sequential)
Comparator: decitabine
Comparator: vorinostat (concurrent)
Additional drug interventions recognized in this trial
Decitabine
Vorinostat
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Anticarcinogenic Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Merck
Back to top of Main Content
